Attached files
| file | filename |
|---|---|
| 10-K - 10-K - PLUS THERAPEUTICS, INC. | pstv-10k_20201231.htm |
| EX-32.1 - EX-32.1 - PLUS THERAPEUTICS, INC. | pstv-ex321_6.htm |
| EX-31.2 - EX-31.2 - PLUS THERAPEUTICS, INC. | pstv-ex312_7.htm |
| EX-31.1 - EX-31.1 - PLUS THERAPEUTICS, INC. | pstv-ex311_9.htm |
| EX-10.24 - EX-10.24 - PLUS THERAPEUTICS, INC. | pstv-ex1024_87.htm |
EXHIBIT 23.1
Consent of Independent Registered Public Accounting Firm
Plus Therapeutics, Inc.
Austin, Texas
We hereby consent to the incorporation by reference in the Registration Statements on Forms S-1 (Nos. 333-229485, 333-227485, 333-226205, 333-224502, 333-219967, 333-215365, 333-210628 and 333-249728), Forms S-3 (Nos. 333-217988, 333-172787, 333-169822, 333-157023, 333-140875, 333-134129, 333-153233, 333-159912, 333-192409, 333-200090, 333-195846, 333-216947 and 333-249410) and Forms S-8 (Nos. 333-223566, 333-210211, 333-202858, 333-181764, 333-122691, 333-82074 and 333-239548) of Plus Therapeutics, Inc. (the “Company”) of our report dated February 22, 2021, relating to the consolidated financial statements, which appears in this Annual Report on Form 10-K. Our report contains an explanatory paragraph regarding the Company’s ability to continue as a going concern.
/s/ BDO USA, LLP
San Diego, California
February 22, 2021